LEVERNA THERAPEUTICS

Dead / Abandoned — Abandoned — no statement of use filed (as of 08 Dec 2025)

What this means for you

This application is over — abandoned 08 Dec 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
98092622
Mark type
Design + words
Filed
19 Jul 2023
Published for opposition
12 Mar 2024
Abandoned
08 Dec 2025
Attorney of record
Perry Gattegno

Goods and services

  • Class 042 — Scientific and technological services: Biochemical research and development; Biotechnology research; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of RNA-targeted drugs; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs; Research and development in the pharmaceutical and biotechnology fields; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Owner

Prosecution history

  • 08 Dec 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 08 Dec 2025 — ABANDONMENT - NO USE STATEMENT FILED
  • 05 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 05 Apr 2025 — SOU EXTENSION 2 GRANTED
  • 04 Apr 2025 — SOU EXTENSION 2 FILED
  • 04 Apr 2025 — SOU TEAS EXTENSION RECEIVED
  • 27 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 27 Aug 2024 — SOU EXTENSION 1 GRANTED
  • 27 Aug 2024 — SOU EXTENSION 1 FILED
  • 27 Aug 2024 — SOU TEAS EXTENSION RECEIVED
  • 07 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 12 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 12 Mar 2024 — PUBLISHED FOR OPPOSITION
  • 21 Feb 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 21 Feb 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

View this trademark record on Marksy